BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferri D, Costero AM, Gaviña P, Parra M, Merino V, Teruel AH, Sancenón F, Martínez-Máñez R. Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis. Int J Pharm 2019;561:93-101. [PMID: 30817986 DOI: 10.1016/j.ijpharm.2019.02.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Soltani F, Kamali H, Akhgari A, Ghasemzadeh Rahbardar M, Afrasiabi Garekani H, Nokhodchi A, Sadeghi F. Preparation and Characterization of a Novel Multiparticulate Dosage Form Carrying Budesonide-Loaded Chitosan Nanoparticles to Enhance the Efficiency of Pellets in the Colon. Pharmaceutics 2022;15. [PMID: 36678698 DOI: 10.3390/pharmaceutics15010069] [Reference Citation Analysis]
2 Tang X, Yang M, Gu Y, Jiang L, Du Y, Liu J. Orally Deliverable Dual-Targeted Pellets for the Synergistic Treatment of Ulcerative Colitis. Drug Des Devel Ther 2021;15:4105-23. [PMID: 34616144 DOI: 10.2147/DDDT.S322702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Cheng S, Shen H, Zhao S, Zhang Y, Xu H, Wang L, Di B, Xu L, Hu C. Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota. Nanoscale 2020;12:15348-63. [PMID: 32648873 DOI: 10.1039/d0nr03037f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
4 Barros M, López-Carrasco A, Amorós P, Gil S, Gaviña P, Parra M, El Haskouri J, Terencio MC, Costero AM. Chromogenic Chemodosimeter Based on Capped Silica Particles to Detect Spermine and Spermidine. Nanomaterials (Basel) 2021;11:818. [PMID: 33806899 DOI: 10.3390/nano11030818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ferreira-Duarte M, Rodrigues-Pinto T, Menezes-Pinto D, Esteves-Monteiro M, Gonçalves-Monteiro S, Capas-Peneda S, Magro F, Dias-Pereira P, Morato M, Duarte-Araújo M. 2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norgevicus: a categorization proposal. Exp Anim 2021;70:245-56. [PMID: 33536378 DOI: 10.1538/expanim.20-0113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Li X, Lu C, Yang Y, Yu C, Rao Y. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed Pharmacother 2020;129:110486. [PMID: 32768972 DOI: 10.1016/j.biopha.2020.110486] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
7 Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, Rey-Bretal D, Lamela-Gómez I, Otero-Espinar FJ, Blanco-Méndez J, Antúnez-López JR, Pombo-Pasín M, Aguiar P, Ruibal Á, Luzardo-Álvarez A, Fernández-Ferreiro A. Evaluation of the therapeutic activity of melatonin and resveratrol in Inflammatory Bowel Disease: A longitudinal PET/CT study in an animal model. Int J Pharm 2019;572:118713. [PMID: 31593809 DOI: 10.1016/j.ijpharm.2019.118713] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]